Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 254.68% | 222.68% | -9.43% | 145.89% | -92.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 254.68% | 222.68% | -9.43% | 145.89% | -92.43% |
| Cost of Revenue | -- | 122.77% | 134.48% | -- | -- |
| Gross Profit | 194.72% | 0.47% | -13.39% | 129.71% | -87.61% |
| SG&A Expenses | 0.82% | 45.50% | -10.40% | 257.72% | 128.94% |
| Depreciation & Amortization | -0.93% | 27.54% | 78.45% | 73.50% | 85.34% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.30% | 110.78% | 10.76% | 237.68% | -10.22% |
| Operating Income | 23.94% | -63.45% | -18.04% | -263.13% | -290.23% |
| Income Before Tax | 15.73% | -60.74% | -22.99% | -241.88% | -1,404.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 15.73% | -60.74% | -22.99% | -241.88% | -1,404.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.73% | -60.74% | -22.99% | -241.88% | -1,404.49% |
| EBIT | 23.94% | -63.45% | -18.04% | -263.13% | -290.23% |
| EBITDA | 21.66% | -60.66% | -19.55% | -287.25% | -265.11% |
| EPS Basic | 28.95% | -50.00% | -2.94% | -194.74% | -1,366.67% |
| Normalized Basic EPS | 36.36% | -54.55% | -4.76% | -191.67% | -1,200.00% |
| EPS Diluted | 28.95% | -50.00% | -2.94% | -194.74% | -1,366.67% |
| Normalized Diluted EPS | 36.36% | -54.55% | -4.76% | -191.67% | -1,200.00% |
| Average Basic Shares Outstanding | 17.30% | 7.95% | 18.10% | 17.09% | 6.48% |
| Average Diluted Shares Outstanding | 17.30% | 7.95% | 18.10% | 17.09% | 4.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |